50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Gold is about to SOAR – here’s what you need to do (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Gold is about to SOAR – here’s what you need to do (Ad)
Closing prices for crude oil, gold and other commodities
Dow sinks to 2022 low as recession fears roil world markets
Gold is about to SOAR – here’s what you need to do (Ad)
'Crucial' vote could move Italy to right; many might boycott
MarketBeat: Week in Review 9/19 – 9/23
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Gold is about to SOAR – here’s what you need to do (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Gold is about to SOAR – here’s what you need to do (Ad)
Closing prices for crude oil, gold and other commodities
Dow sinks to 2022 low as recession fears roil world markets
Gold is about to SOAR – here’s what you need to do (Ad)
'Crucial' vote could move Italy to right; many might boycott
MarketBeat: Week in Review 9/19 – 9/23
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Gold is about to SOAR – here’s what you need to do (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Gold is about to SOAR – here’s what you need to do (Ad)
Closing prices for crude oil, gold and other commodities
Dow sinks to 2022 low as recession fears roil world markets
Gold is about to SOAR – here’s what you need to do (Ad)
'Crucial' vote could move Italy to right; many might boycott
MarketBeat: Week in Review 9/19 – 9/23
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Gold is about to SOAR – here’s what you need to do (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Gold is about to SOAR – here’s what you need to do (Ad)
Closing prices for crude oil, gold and other commodities
Dow sinks to 2022 low as recession fears roil world markets
Gold is about to SOAR – here’s what you need to do (Ad)
'Crucial' vote could move Italy to right; many might boycott
MarketBeat: Week in Review 9/19 – 9/23
NASDAQ:PRTK

Paratek Pharmaceuticals - PRTK Stock Forecast, Price & News

$2.29
-0.06 (-2.55%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.27
$2.37
50-Day Range
$2.25
$2.93
52-Week Range
$1.60
$5.42
Volume
341,684 shs
Average Volume
306,670 shs
Market Capitalization
$125.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Paratek Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Strong Buy
3.50 Rating Score
Upside/​Downside
787.9% Upside
$20.33 Price Target
Short Interest
Bearish
9.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.98
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$306,477 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.92) to $0.48 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

873rd out of 1,080 stocks

Pharmaceutical Preparations Industry

418th out of 535 stocks

PRTK stock logo

About Paratek Pharmaceuticals (NASDAQ:PRTK) Stock

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PRTK Stock News Headlines

Paratek Pharmaceuticals (NASDAQ: PRTK)
Paratek Pharmaceuticals Q1 2022 Earnings Preview
Paratek: Q4 Earnings Snapshot
See More Headlines
Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PRTK Company Calendar

Last Earnings
11/08/2021
Today
9/24/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PRTK
Previous Symbol
NASDAQ:TSPT
CUSIP
89354M10
Employees
207
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$20.33
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+576.9%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Net Income
$-59,080,000.00
Pretax Margin
-77.10%

Debt

Sales & Book Value

Annual Sales
$130.16 million
Book Value
($2.62) per share

Miscellaneous

Free Float
50,474,000
Market Cap
$125.63 million
Optionable
Optionable
Beta
1.48

Social Links


Key Executives

  • Mr. Michael F. Bigham CPAMr. Michael F. Bigham CPA (Age 64)
    CPA, M.B.A., MBA, Exec. Chairman
    Comp: $934.7k
  • Dr. Evan Loh FACC (Age 63)
    FAHA, M.D., CEO & Director
    Comp: $1.07M
  • Mr. Adam WoodrowMr. Adam Woodrow (Age 55)
    Pres & Chief Commercial Officer
    Comp: $735.48k
  • Ms. Sarah Higgins (Age 47)
    VP of Fin., Controller & Principal Accounting Officer
  • Mr. Jason Burdette
    Sr. VP of Technical Operations
  • Mr. Ben Strain
    VP of Investor Relations & Corp. Communications and Chief of Staff to the CEO
  • Mr. William M. HaskelMr. William M. Haskel (Age 60)
    Sr. VP, Chief Legal Officer, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
  • Ms. Karen McGrath
    Sr. VP of HR
  • Mr. Randall B. BrennerMr. Randall B. Brenner (Age 49)
    Chief Devel. & Regulatory Officer













PRTK Stock - Frequently Asked Questions

Should I buy or sell Paratek Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" PRTK shares.
View PRTK analyst ratings
or view top-rated stocks.

What is Paratek Pharmaceuticals' stock price forecast for 2022?

2 Wall Street research analysts have issued 12-month price targets for Paratek Pharmaceuticals' shares. Their PRTK share price forecasts range from $11.00 to $30.00. On average, they anticipate the company's share price to reach $20.33 in the next twelve months. This suggests a possible upside of 787.9% from the stock's current price.
View analysts price targets for PRTK
or view top-rated stocks among Wall Street analysts.

How have PRTK shares performed in 2022?

Paratek Pharmaceuticals' stock was trading at $4.49 at the beginning of the year. Since then, PRTK stock has decreased by 49.0% and is now trading at $2.29.
View the best growth stocks for 2022 here
.

When is Paratek Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our PRTK earnings forecast
.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.08. The specialty pharmaceutical company had revenue of $24.45 million for the quarter, compared to analysts' expectations of $22.98 million. During the same period in the prior year, the company posted ($0.46) EPS.

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $155.00 million-$170.00 million, compared to the consensus revenue estimate of $163.89 million.

What other stocks do shareholders of Paratek Pharmaceuticals own?
What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include General American Investors Co. Inc. (3.22%), Millennium Management LLC (0.92%), 1492 Capital Management LLC (0.89%), Pictet Asset Management SA (0.88%), Renaissance Technologies LLC (0.54%) and State Street Corp (0.39%). Insiders that own company stock include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner and William M Haskel.
View institutional ownership trends
.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $2.29.

How much money does Paratek Pharmaceuticals make?

Paratek Pharmaceuticals (NASDAQ:PRTK) has a market capitalization of $125.64 million and generates $130.16 million in revenue each year. The specialty pharmaceutical company earns $-59,080,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

How many employees does Paratek Pharmaceuticals have?

The company employs 207 workers across the globe.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The official website for the company is www.paratekpharma.com. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at ir@paratekpharma.com, or via fax at 617-275-0039.

This page (NASDAQ:PRTK) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.